ArticleJournal of cancer research and clinical oncology2019

Co-mutation of TP53 and PIK3CA in residual disease after neoadjuvant chemotherapy is associated with poor survival in breast cancer.

Xinyi Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.